• Publications
  • Influence
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
TLDR
Optimal responders to chronic myeloid leukemia treatment should continue therapy indefinitely, with careful surveillance, or they can be enrolled in controlled studies of treatment discontinuation once a deeper molecular response is achieved. Expand
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.
TLDR
The acquisition of a T674I resistance mutation at the time of relapse demonstrates that FIP1L1-PDGFRalpha is the target of imatinib, and data indicate that the deletion of genetic material may result in gain-of-function fusion proteins. Expand
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.
TLDR
Imatinib should be continued indefinitely in optimal responders and second-generation TKIs are recommended, followed by allogeneic hematopoietic stem-cell transplantation only in instances of failure and, sometimes, suboptimal response, depending on transplantation risk. Expand
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
TLDR
Dasatinib induces hematologic and cytogenetic responses in patients with CML or Ph-positive ALL who cannot tolerate or are resistant to imatinib, which is effective in Philadelphia chromosome-positive leukemias but relapse occurs. Expand
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
TLDR
Nilotinib has a relatively favorable safety profile and is active in imatinib-resistant CML, and common adverse events were myelosuppression, transient indirect hyperbilirubinemia, and rashes. Expand
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
TLDR
It is recommended that the preferred initial treatment for most patients newly diagnosed in chronic phase should now be 400 mg IM daily and the value of IM (400 mg/day) and of conventional allogeneic hematopoietic stem cell transplantation (alloHSCT) is confirmed. Expand
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
TLDR
Ponatinib was highly active in heavily pretreated patients with Ph-positive leukemias with resistance to tyrosine kinase inhibitors, including patients with the BCR-ABL T315I mutation, other mutations, or no mutations. Expand
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a
TLDR
The combination of P with H and standard chemotherapy resulted in low rates of symptomatic LVSD, and the tolerability of H and P with chemotherapy in the neoadjuvant treatment of HER2-positive early breast cancer was assessed. Expand
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.
TLDR
It is reported that human CML stem cells do not depend on BCR-ABL activity for survival and are thus not eliminated by imatinib therapy, suggesting that primitive CML cells are not oncogene addicted and that therapies that biochemically target BCR -ABL will not eliminate C ML stem cells. Expand
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
TLDR
FCR produced a high CR rate in previously untreated CLL, and most patients had no detectable disease on flow cytometry at the end of therapy. Expand
...
1
2
3
4
5
...